Loading... Please wait...
Contact Us
Would you like more
information on this report
Please contact us today at +44(0)20.7665.9240
or +1 212.220.0880
or write to us.

Atopic Dermatitis: Update Bulletin #3 [June 2018]

Product Code:
596200979
Publication Date:
June 2018
Format:
PDF
Price:
$1,095

This edition presents key opinion leader (KOL) views on recent developments in the Atopic Dermatitis (AD) market. Topics covered include; AnaptysBio presenting updated data from a Phase IIa trial of the anti-interleukin (IL)-33 antibody ANB020 in patients with moderate-to-severe AD; Glenmark Pharmaceuticals presenting new Phase IIa data for its anti-OX40 monoclonal antibody (mAb) GBR 830; XBiotech announcing that the first patient had been treated in a Phase II study evaluating the human-derived anti-IL-1 alpha antibody MABp1 as a therapy for moderate-to-severe AD.

Business Questions:

• To what extent do the updated Phase IIa results confirm ANB020’s potential as an effective therapy for AD?
• Do KOLs think that targeting IL-33 constitutes a safe and effective approach for treating AD?
• How do KOLs think that ANB020 would be utilised within the treatment algorithm if it received marketing authorisation for AD?
• Are the new Phase IIa results adequate for assessing GBR 830’s potential as an AD therapy or will further study be required?
• Does OX40 receptor inhibition represent a safe and effective method for treating AD?
• Where do KOLs think that GBR 830 will be positioned within the treatment paradigm if it receives regulatory approval as an AD therapy?
• How effective is IL-1 alpha inhibition likely to be as a means to reduce the inflammation associated with AD?
• Do KOLs expect to see any adverse effects associated with the use of MABp1 as a therapy for AD?
• Is it possible to predict with any confidence what sort of role MABp1 will play in the treatment of AD or is it too early to draw any meaningful conclusions?




customer.service@firstwordpharma.com

All Contents Copyright © 2018 Doctor's Guide Publishing Limited All Rights Reserved